CATALYST is a phase 3 study of bardoxolone methyl in patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH).

**About the Study**
- Treatment: Bardoxolone methyl or placebo capsules taken by mouth once daily for 24 weeks.
- Approximately 11 visits over 28 weeks.
- Primary endpoint: Change in 6 minute walk distance.
- Cost of travel may be reimbursed.

**Criteria for Participation**
- Between ages 18 and 75.
- Diagnosis of WHO group 1 PAH associated with connective tissue disease.
- Not currently taking more than 2 approved PAH therapies.
- IV or subcutaneous prostacyclins not allowed.

**Global Study Centers**
- A complete list of participating study centers and contact information can be found on the clinicaltrials.gov listing.

**Logo and Information**
- Go to www.clinicaltrials.gov/ct2/show/NCT02657356 for more information.